Pauline Soulas-Sprauel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pauline Soulas-Sprauel has a total of 359 co-authors. Here are the top co-authors by number of shared publications:
- Anne-Sophie Korganow
Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, University Hospitals of Strasbourg, Strasbourg, France
18 shared publications Thierry Martin
CNRS UPR 3572 "Immunopathology and Therapeutic Chemistry"/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC), Strasbourg, France; UFR Médecine, Université de Strasbourg, Strasbourg, France; Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
17 shared publicationsAnne-Marie Knapp
CNRS UPR 3572 "Immunopathology and Therapeutic Chemistry"/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC), Strasbourg, France; UFR Médecine, Université de Strasbourg, Strasbourg, France
6 shared publications- Vincent Gies
Department of Clinical Immunology and Internal Medicine, National Reference Center for Systemic Autoimmune Diseases (CNR RESO), Tertiary Center for Primary Immunodeficiency, Strasbourg University Hospital, Strasbourg, France
6 shared publications - Frédéric Rieux-Laucat
Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, Imagine Institute, Université Paris Cité, INSERM UMR 1163, Paris, France
5 shared publications Jean-Louis Pasquali
CNRS UPR 3572 "Immunopathology and Therapeutic Chemistry"/Laboratory of Excellence Medalis, Institute of Molecular and Cellular Biology (IBMC), Strasbourg, France; Department of Clinical Immunology and Internal Medicine, National Reference Center for Autoimmune Diseases, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; UFR Médecine, Université de Strasbourg, Strasbourg, France
5 shared publications
Latest Publications
- Open Access
- 13 August 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (9) , 2438-2461
Lymphopenia drives T cell exhaustion in immunodeficient STING gain-of-function mice
STING gain-of-function (GOF) mutations cause STING-Associated Vasculopathy with onset in Infancy (SAVI), a severe autoinflammatory disease. Mice carrying STING GOF V154M mutation develop profound T cell lymphopenia, partly due to impaired thymic development. To investigate the mechanisms of peripheral T cell dysfunctions, we analyzed transcriptomic and phenotypic profiles of splenic T cells from these mice. We found a terminally exhausted T cell phenotype, established early in life upon entry into the periphery, independent of type I interferons and intrinsic STING activation in T cells or stromal cells. Mechanistically, naive T cells in the lymphopenic periphery experienced heightened stimulation of the IL-7 receptor and TCR, including NFAT pathway, a key factor in T cell exhaustion. Transplantation of STING GOF hematopoietic stem cells with wild-type bone marrow prevented exhaustion in this non-lymphopenic context, placing lymphopenia as a key driver. T cell exhaustion was also observed in lymphopenic mice carrying Rag1 hypomorphic mutations. In conclusion, our results highlight T cell exhaustion induced by lymphopenia and could have important implications for the management of patients with severe immune deficiencies.
- 13 August 2025
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 17 (9) , 2438-2461
Open AccessLymphopenia drives T cell exhaustion in immunodeficient STING gain-of-function mice
STING gain-of-function (GOF) mutations cause STING-Associated Vasculopathy with onset in Infancy (SAVI), a severe autoinflammatory disease. Mice carrying STING GOF V154M mutation develop profound T cell lymphopenia, partly due to impaired thymic development. To investigate the mechanisms of peripheral T cell dysfunctions, we analyzed transcriptomic and phenotypic profiles of splenic T cells from these mice. We found a terminally exhausted T cell phenotype, established early in life upon entry into the periphery, independent of type I interferons and intrinsic STING activation in T cells or stromal cells. Mechanistically, naive T cells in the lymphopenic periphery experienced heightened stimulation of the IL-7 receptor and TCR, including NFAT pathway, a key factor in T cell exhaustion. Transplantation of STING GOF hematopoietic stem cells with wild-type bone marrow prevented exhaustion in this non-lymphopenic context, placing lymphopenia as a key driver. T cell exhaustion was also observed in lymphopenic mice carrying Rag1 hypomorphic mutations. In conclusion, our results highlight T cell exhaustion induced by lymphopenia and could have important implications for the management of patients with severe immune deficiencies.
- Open Access
Lymphopenia drives T cell exhaustion in immunodeficient STING gain-of-function mice
STING gain-of-function (GOF) mutations are associated with the severe autoinflammatory disease designated STING Associated Vasculopathy with onset in Infancy (SAVI). Mice with the STING GOF V154M mutation develop profound T cell lymphopenia, partly due to a blockage of T cell development in the thymus. To better characterize the mechanisms of peripheral T cell dysfunctions, we conducted a transcriptomic and phenotypic analysis on sorted splenic CD4+ and CD8+ mature T cells from STING GOF V154M mice. We identify a T cell exhaustion phenotype that manifests at a terminal stage, acquired early in life but only after reaching the peripheral environment. This phenotype is independent of type I interferons and does not rely on intrinsic STING activation in either T cells or stromal cells. Mechanistically, the limited number of mature T cells that reach the periphery appear to be quickly impacted by the lymphopenic environment, experiencing heightened stimulation of the IL-7 receptor and TCR pathways, including the NFAT pathway, a key factor in T cell exhaustion. By performing transplantation experiments with STING GOF long term-hematopoietic stem cells (LT-HSCs) along with supportive wild-type bone marrow (BM) cells, we were able to prevent the T cell exhaustion of STING GOF T cells in the resulting non-lymphopenic context, demonstrating that lymphopenia is a major driver of T cell exhaustion in STING GOF mice. T cell exhaustion, although less severe, was also observed in lymphopenic mice carrying Rag1 hypomorphic mutations. In conclusion, our results, which highlight T cell exhaustion induced by lymphopenia, could have important implications for the management of patients with severe immune deficiencies. Highlights: We describe a phenotype of T cell exhaustion in STING GOF V154M mice, which is acquired early in life and in the periphery. STING GOF-associated T cell exhaustion is independent of type I IFNs, and STING GOF/activation in T cells or in stromal cells is not sufficient for T cell exhaustion. Lymphopenia is a major driver of T cell exhaustion in STING GOF mice, and increased antigenic/IL-7 stimulation of T cells in the lymphopenic context of STING GOF mice could be implicated in the induction of T cell exhaustion.
Open AccessLymphopenia drives T cell exhaustion in immunodeficient STING gain-of-function mice
STING gain-of-function (GOF) mutations are associated with the severe autoinflammatory disease designated STING Associated Vasculopathy with onset in Infancy (SAVI). Mice with the STING GOF V154M mutation develop profound T cell lymphopenia, partly due to a blockage of T cell development in the thymus. To better characterize the mechanisms of peripheral T cell dysfunctions, we conducted a transcriptomic and phenotypic analysis on sorted splenic CD4+ and CD8+ mature T cells from STING GOF V154M mice. We identify a T cell exhaustion phenotype that manifests at a terminal stage, acquired early in life but only after reaching the peripheral environment. This phenotype is independent of type I interferons and does not rely on intrinsic STING activation in either T cells or stromal cells. Mechanistically, the limited number of mature T cells that reach the periphery appear to be quickly impacted by the lymphopenic environment, experiencing heightened stimulation of the IL-7 receptor and TCR pathways, including the NFAT pathway, a key factor in T cell exhaustion. By performing transplantation experiments with STING GOF long term-hematopoietic stem cells (LT-HSCs) along with supportive wild-type bone marrow (BM) cells, we were able to prevent the T cell exhaustion of STING GOF T cells in the resulting non-lymphopenic context, demonstrating that lymphopenia is a major driver of T cell exhaustion in STING GOF mice. T cell exhaustion, although less severe, was also observed in lymphopenic mice carrying Rag1 hypomorphic mutations. In conclusion, our results, which highlight T cell exhaustion induced by lymphopenia, could have important implications for the management of patients with severe immune deficiencies. Highlights: We describe a phenotype of T cell exhaustion in STING GOF V154M mice, which is acquired early in life and in the periphery. STING GOF-associated T cell exhaustion is independent of type I IFNs, and STING GOF/activation in T cells or in stromal cells is not sufficient for T cell exhaustion. Lymphopenia is a major driver of T cell exhaustion in STING GOF mice, and increased antigenic/IL-7 stimulation of T cells in the lymphopenic context of STING GOF mice could be implicated in the induction of T cell exhaustion.
- 9 December 2023
- Published by Elsevier in Journal of Autoimmunity
- Vol. 142, 103152
Loss of function of XBP1 splicing activity of IRE1α favors B cell tolerance breakdown
- 9 December 2023
- Published by Elsevier in Journal of Autoimmunity
- Vol. 142, 103152
Loss of function of XBP1 splicing activity of IRE1α favors B cell tolerance breakdown
- 24 March 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (9) , 1209-1221
mTOR Activation Underlies Enhanced B Cell Proliferation and Autoimmunity in PrkcdG510S/G510S Mice
Autosomal recessive PRKCD deficiency has previously been associated with the development of systemic lupus erythematosus in human patients, but the mechanisms underlying autoimmunity remain poorly understood. We introduced the Prkcd G510S mutation that we previously associated to a Mendelian cause of systemic lupus erythematosus in the mouse genome, using CRISPR-Cas9 gene editing. PrkcdG510S/G510S mice recapitulated the human phenotype and had reduced lifespan. We demonstrate that this phenotype is linked to a B cell–autonomous role of Prkcd. A detailed analysis of B cell activation in PrkcdG510S/G510S mice shows an upregulation of the PI3K/mTOR pathway after the engagement of the BCR in these cells, leading to lymphoproliferation. Treatment of mice with rapamycin, an mTORC1 inhibitor, significantly improves autoimmune symptoms, demonstrating in vivo the deleterious effect of mTOR pathway activation in PrkcdG510S/G510S mice. Additional defects in PrkcdG510S/G510S mice include a decrease in peripheral mature NK cells that might contribute to the known susceptibility to viral infections of patients with PRKCD mutations.
- 24 March 2023
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 210 (9) , 1209-1221
mTOR Activation Underlies Enhanced B Cell Proliferation and Autoimmunity in PrkcdG510S/G510S Mice
Autosomal recessive PRKCD deficiency has previously been associated with the development of systemic lupus erythematosus in human patients, but the mechanisms underlying autoimmunity remain poorly understood. We introduced the Prkcd G510S mutation that we previously associated to a Mendelian cause of systemic lupus erythematosus in the mouse genome, using CRISPR-Cas9 gene editing. PrkcdG510S/G510S mice recapitulated the human phenotype and had reduced lifespan. We demonstrate that this phenotype is linked to a B cell–autonomous role of Prkcd. A detailed analysis of B cell activation in PrkcdG510S/G510S mice shows an upregulation of the PI3K/mTOR pathway after the engagement of the BCR in these cells, leading to lymphoproliferation. Treatment of mice with rapamycin, an mTORC1 inhibitor, significantly improves autoimmune symptoms, demonstrating in vivo the deleterious effect of mTOR pathway activation in PrkcdG510S/G510S mice. Additional defects in PrkcdG510S/G510S mice include a decrease in peripheral mature NK cells that might contribute to the known susceptibility to viral infections of patients with PRKCD mutations.
- 1 March 2019
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (3) , 1038-1041.e4
Campylobacter infection in adult patients with primary antibody deficiency
- 1 March 2019
- Published by Elsevier in The Journal of Allergy and Clinical Immunology: In Practice
- Vol. 7 (3) , 1038-1041.e4
Campylobacter infection in adult patients with primary antibody deficiency
- 1 February 2019
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 143 (2) , 712-725.e5
Severe combined immunodeficiency in stimulator of interferon genes (STING) V154M/wild-type mice
- 1 February 2019
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 143 (2) , 712-725.e5
Severe combined immunodeficiency in stimulator of interferon genes (STING) V154M/wild-type mice
- Open Access
- 10 January 2019
- Published by BMJ in Lupus Science & Medicine
- Vol. 6 (1) , e000303
10 most important contemporary challenges in the management of SLE
From a 1-year survival of less than 50% before the discovery of glucocorticoids to over 90% at 10 years in most dedicated centres, the spectrum of SLE has profoundly evolved. Despite this improvement, several major challenges currently remain. The aim of this review is to analyse what are, according to us, the 10 most important contemporary challenges in the management of SLE. Among those are the need to treat to target to favour disease remission (or low disease activity), limit the use of glucocorticoids, derive more comprehensive tools for the evaluation of disease activity, develop more effective drugs (yielding successful trials), dissect the heterogeneity of the disease both at the molecular and genetic levels, identify relevant biomarkers for individualised treatment, manage fertility and pregnancy, tackle comorbidities such as cardiovascular risk, the prevention of infections and osteoporosis, improve the network of care (from the patients’ perspective), and favour a holistic approach (integrating fatigue, adherence to treatment, physical activity). Altogether, these 10 contemporary challenges in SLE may be considered as a roadmap for those involved in the daily care of patients with SLE, as well as for researchers who may wish to contribute to an improved management of this rare and complex disease.
- 10 January 2019
- Published by BMJ in Lupus Science & Medicine
- Vol. 6 (1) , e000303
Open Access10 most important contemporary challenges in the management of SLE
From a 1-year survival of less than 50% before the discovery of glucocorticoids to over 90% at 10 years in most dedicated centres, the spectrum of SLE has profoundly evolved. Despite this improvement, several major challenges currently remain. The aim of this review is to analyse what are, according to us, the 10 most important contemporary challenges in the management of SLE. Among those are the need to treat to target to favour disease remission (or low disease activity), limit the use of glucocorticoids, derive more comprehensive tools for the evaluation of disease activity, develop more effective drugs (yielding successful trials), dissect the heterogeneity of the disease both at the molecular and genetic levels, identify relevant biomarkers for individualised treatment, manage fertility and pregnancy, tackle comorbidities such as cardiovascular risk, the prevention of infections and osteoporosis, improve the network of care (from the patients’ perspective), and favour a holistic approach (integrating fatigue, adherence to treatment, physical activity). Altogether, these 10 contemporary challenges in SLE may be considered as a roadmap for those involved in the daily care of patients with SLE, as well as for researchers who may wish to contribute to an improved management of this rare and complex disease.
- Open Access
- 15 March 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 373
Trib1 Is Overexpressed in Systemic Lupus Erythematosus, While It Regulates Immunoglobulin Production in Murine B Cells
Systemic lupus erythematosus (SLE) is a severe and heterogeneous autoimmune disease with a complex genetic etiology, characterized by the production of various pathogenic autoantibodies, which participate in end-organ damages. The majority of human SLE occurs in adults as a polygenic disease, and clinical flares interspersed with silent phases of various lengths characterize the usual evolution of the disease in time. Trying to understand the mechanism of the different phenotypic traits of the disease, and considering the central role of B cells in SLE, we previously performed a detailed wide analysis of gene expression variation in B cells from quiescent SLE patients. This analysis pointed out an overexpression of TRIB1. TRIB1 is a pseudokinase that has been implicated in the development of leukemia and also metabolic disorders. It is hypothesized that Trib1 plays an adapter or scaffold function in signaling pathways, notably in MAPK pathways. Therefore, we planned to understand the functional significance of TRIB1 overexpression in B cells in SLE. We produced a new knock-in model with B-cell-specific overexpression of Trib1. We showed that overexpression of Trib1 specifically in B cells does not impact B cell development nor induce any development of SLE symptoms in the mice. By contrast, Trib1 has a negative regulatory function on the production of immunoglobulins, notably IgG1, but also on the production of autoantibodies in an induced model. We observed a decrease of Erk activation in BCR-stimulated Trib1 overexpressing B cells. Finally, we searched for Trib1 partners in B cells by proteomic analysis in order to explore the regulatory function of Trib1 in B cells. Interestingly, we find an interaction between Trib1 and CD72, a negative regulator of B cells whose deficiency in mice leads to the development of autoimmunity. In conclusion, the overexpression of Trib1 could be one of the molecular pathways implicated in the negative regulation of B cells during SLE.
- 15 March 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 373
Open AccessTrib1 Is Overexpressed in Systemic Lupus Erythematosus, While It Regulates Immunoglobulin Production in Murine B Cells
Systemic lupus erythematosus (SLE) is a severe and heterogeneous autoimmune disease with a complex genetic etiology, characterized by the production of various pathogenic autoantibodies, which participate in end-organ damages. The majority of human SLE occurs in adults as a polygenic disease, and clinical flares interspersed with silent phases of various lengths characterize the usual evolution of the disease in time. Trying to understand the mechanism of the different phenotypic traits of the disease, and considering the central role of B cells in SLE, we previously performed a detailed wide analysis of gene expression variation in B cells from quiescent SLE patients. This analysis pointed out an overexpression of TRIB1. TRIB1 is a pseudokinase that has been implicated in the development of leukemia and also metabolic disorders. It is hypothesized that Trib1 plays an adapter or scaffold function in signaling pathways, notably in MAPK pathways. Therefore, we planned to understand the functional significance of TRIB1 overexpression in B cells in SLE. We produced a new knock-in model with B-cell-specific overexpression of Trib1. We showed that overexpression of Trib1 specifically in B cells does not impact B cell development nor induce any development of SLE symptoms in the mice. By contrast, Trib1 has a negative regulatory function on the production of immunoglobulins, notably IgG1, but also on the production of autoantibodies in an induced model. We observed a decrease of Erk activation in BCR-stimulated Trib1 overexpressing B cells. Finally, we searched for Trib1 partners in B cells by proteomic analysis in order to explore the regulatory function of Trib1 in B cells. Interestingly, we find an interaction between Trib1 and CD72, a negative regulator of B cells whose deficiency in mice leads to the development of autoimmunity. In conclusion, the overexpression of Trib1 could be one of the molecular pathways implicated in the negative regulation of B cells during SLE.
- Open Access
- 8 March 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (5)
Impaired TLR9 responses in B cells from patients with systemic lupus erythematosus
B cells play a central role in systemic lupus erythematosus (SLE) pathophysiology but dysregulated pathways leading to a break in B cell tolerance remain unclear. Since Toll-like receptor 9 (TLR9) favors the elimination of autoreactive B cells in the periphery, we assessed TLR9 function in SLE by analyzing the responses of B cells and plasmacytoid dendritic cells (pDCs) isolated from healthy donors and patients after stimulation with CpG, a TLR9 agonist. We found that SLE B cells from patients without hydroxychloroquine treatment displayed defective in vitro TLR9 responses, as illustrated by the impaired upregulation of B cell activation molecules and the diminished production of various cytokines including antiinflammatory IL-10. In agreement with CD19 controlling TLR9 responses in B cells, decreased expression of the CD19/CD21 complex on SLE B cells was detected as early as the transitional B cell stage. In contrast, TLR7 function was preserved in SLE B cells, whereas pDCs from SLE patients properly responded to TLR9 stimulation, thereby revealing that impaired TLR9 function in SLE was restricted to B cells. We conclude that abnormal CD19 expression and TLR9 tolerogenic function in SLE B cells may contribute to the break of B cell tolerance in these patients.
- 8 March 2018
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 3 (5)
Open AccessImpaired TLR9 responses in B cells from patients with systemic lupus erythematosus
B cells play a central role in systemic lupus erythematosus (SLE) pathophysiology but dysregulated pathways leading to a break in B cell tolerance remain unclear. Since Toll-like receptor 9 (TLR9) favors the elimination of autoreactive B cells in the periphery, we assessed TLR9 function in SLE by analyzing the responses of B cells and plasmacytoid dendritic cells (pDCs) isolated from healthy donors and patients after stimulation with CpG, a TLR9 agonist. We found that SLE B cells from patients without hydroxychloroquine treatment displayed defective in vitro TLR9 responses, as illustrated by the impaired upregulation of B cell activation molecules and the diminished production of various cytokines including antiinflammatory IL-10. In agreement with CD19 controlling TLR9 responses in B cells, decreased expression of the CD19/CD21 complex on SLE B cells was detected as early as the transitional B cell stage. In contrast, TLR7 function was preserved in SLE B cells, whereas pDCs from SLE patients properly responded to TLR9 stimulation, thereby revealing that impaired TLR9 function in SLE was restricted to B cells. We conclude that abnormal CD19 expression and TLR9 tolerogenic function in SLE B cells may contribute to the break of B cell tolerance in these patients.
- Open Access
- 16 October 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 13232
Phenotyping of autoreactive B cells with labeled nucleosomes in 56R transgenic mice
The phenotypic characterization of self-reactive B cells producing autoantibodies is one of the challenges to get further insight in the physiopathology of autoimmune diseases. We took advantage of our previously developed flow cytometry method, using labeled nucleosomes, prominent autoantigens in systemic lupus erythematosus, to analyze the phenotype of self-reactive B cells in the anti-DNA B6.56R mouse model. We showed that splenic anti-nucleosome B cells express mostly kappa light chains and harbor a marginal zone phenotype. Moreover, these autoreactive B cells fail to acquire a germinal center phenotype and are less abundant in the transitional T3 compartment. In conclusion, the direct detection of autoreactive B cells helped determine their phenotypic characteristics and provided a more direct insight into the B cell tolerance process in B6.56R mice. This method constitutes an interesting new tool to study the mechanisms of B cell tolerance breakdown in B6.56R mice crossed with autoimmune prone models.
- 16 October 2017
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 13232
Open AccessPhenotyping of autoreactive B cells with labeled nucleosomes in 56R transgenic mice
The phenotypic characterization of self-reactive B cells producing autoantibodies is one of the challenges to get further insight in the physiopathology of autoimmune diseases. We took advantage of our previously developed flow cytometry method, using labeled nucleosomes, prominent autoantigens in systemic lupus erythematosus, to analyze the phenotype of self-reactive B cells in the anti-DNA B6.56R mouse model. We showed that splenic anti-nucleosome B cells express mostly kappa light chains and harbor a marginal zone phenotype. Moreover, these autoreactive B cells fail to acquire a germinal center phenotype and are less abundant in the transitional T3 compartment. In conclusion, the direct detection of autoreactive B cells helped determine their phenotypic characteristics and provided a more direct insight into the B cell tolerance process in B6.56R mice. This method constitutes an interesting new tool to study the mechanisms of B cell tolerance breakdown in B6.56R mice crossed with autoimmune prone models.